FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

FDA Withdraws 5 Bacitracin ANDAs

Federal Register notice: FDA withdraws approval of five Bacitracin for injection ANDAs from multiple holders Akorn, Mylan, Pfizer, XGen Pharmaceutica...

Medical Devices

Roche Covid/Influenza Assay False Positives: FDA

FDA alerts health care providers and laboratory staff about false positive results which can occur with the Roche Molecular Systems cobas SARS-CoV-2 a...

Medical Devices

Combat Medical Recalls Convenience Kits

Combat Medical Systems recalls its Valkyrie LTOWB Collection, Valkyrie LTOWB Administration, Low Titer Type O FWB Transfusion Set, Fresh Whole Blood T...

Human Drugs

Marius Pharmaceuticals Testosterone NDA Accepted

FDA accepts for review a Marius Pharmaceuticals NDA for Kyzatrex (oral testosterone undecanoate) for primary and secondary male hypogonadism.

Biologics

AstraZeneca Nearing EUA Request for Covid Vaccine

AstraZeneca plans to seek an emergency use authorization for its Covid-19 vaccine by early April after determining that it has met FDA data requiremen...

Medical Devices

FDA Clears Baxter Next-Gen Dialysis Machine

FDA clears a Baxter International 510(k) for its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable sys...

Human Drugs

Boehringer Scraps Covid Therapy Due to Lack of Benefit

Boehringer Ingelheim discontinues a Phase 2 trial of a first-in-class compound for reducing the risk or severity of acute respiratory distress syndrom...

FDA General

FDA Covid Lessons Learned

FDA acting commissioner Janet Woodcock discusses two lessons learned about clinical research from the Covid-19 pandemic.

Human Drugs

FDA Extends Review Date for Kadmons Belumosudil

FDA extends the PDUFA review date for Kadmons belumosudil for three months to review additional information submitted by the company.

Federal Register

Info Collection on Prescription Drug Marketing

Federal Register notice: FDA seeks comments on an information collection extension entitled Prescription Drug Marketing 21 CFR Part 203.